PMID- 27409420
OWN - NLM
STAT- MEDLINE
DCOM- 20180122
LR  - 20220311
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 31
DP  - 2016 Aug 2
TI  - Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric 
      cancer: a multicenter prospective observational cohort study.
PG  - 50656-50665
LID - 10.18632/oncotarget.10456 [doi]
AB  - INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in 
      HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression 
      treatment. So, it is worth evaluating the efficacy of continuing trastuzumab 
      after failure of the first-line trastuzumab based treatment. METHODS: 59 patients 
      were enrolled from Zhongshan Hospital Fudan University, Sun Yat-sen University 
      Cancer Center and Peking University Cancer Hospital between September 2012 and 
      Oct 2015. Patients were divided into two groups according to the second line 
      regimens: with or without trastuzumab. The primary endpoint was progression free 
      survival of second line therapy (PFS2). Secondary end points included overall 
      survival (OS), response rate, and adverse events (AEs). RESULTS: Baseline factors 
      were well balanced between two groups. 32 patients treated with trastuzumab plus 
      second line chemotherapy (group A) and 27 patients received chemotherapy alone 
      (group B). The median follow-up time was 7.60 months (range 1.50-32.50). Longer 
      median PFS2 was observed in group A than in group B (3.1 vs 2.0 months, P=0.008). 
      There was no significant differences of median OS2 calculating from the second 
      line therapy (10.5 vs 6.5 months, P=0.172) between two groups. Response rate was 
      9.3% in group A compared with 3.7% in group B (P=0.617). AEs were similar in two 
      groups including cardiac safety. Subgroup analysis showed that factors of male, 
      age<65, good performance status, HER2 immunohistochemical (IHC) 2+ and poor 
      response to first line indicated superior PFS2 in patients continuing trastuzumab 
      to those treated with chemotherapy alone. CONCLUSION: Continuing treatment of 
      trastuzumab beyond first line therapy progression showed effective and safe in 
      AGC.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Jiang, Huiqin
AU  - Jiang H
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Hong
AU  - Li H
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Xu, Ruihua
AU  - Xu R
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China, Guangzhou, China.
FAU - Shen, Lin
AU  - Shen L
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      and Institute, Beijing, China.
FAU - Yu, Yiyi
AU  - Yu Y
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Cui, Yuehong
AU  - Cui Y
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Yu, Shan
AU  - Yu S
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Liu, Tianshu
AU  - Liu T
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*metabolism
MH  - Stomach Neoplasms/*drug therapy/metabolism
MH  - Trastuzumab/*administration & dosage
MH  - Treatment Outcome
PMC - PMC5226611
OTO - NOTNLM
OT  - HER2
OT  - advanced gastric cancer
OT  - trastuzumab
OT  - treatment beyond progression
COIS- All authors declared that they have no conflicts of interest to this work.
EDAT- 2016/07/14 06:00
MHDA- 2018/01/23 06:00
PMCR- 2016/08/02
CRDT- 2016/07/14 06:00
PHST- 2016/03/18 00:00 [received]
PHST- 2016/04/28 00:00 [accepted]
PHST- 2016/07/14 06:00 [pubmed]
PHST- 2018/01/23 06:00 [medline]
PHST- 2016/07/14 06:00 [entrez]
PHST- 2016/08/02 00:00 [pmc-release]
AID - 10456 [pii]
AID - 10.18632/oncotarget.10456 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Aug 2;7(31):50656-50665. doi: 10.18632/oncotarget.10456.